Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt

Thalassemia: early-phase trial registry

5 of 21 indexed Thalassemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 5 currently recruiting · #797 of 28,707 conditions by registered trial count

Thalassemia: 21 US clinical trials tracked, 5 recruiting.

Thalassemia is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is UCSF Benioff Children's Hospital Oakland, running 2 of these trials.

Enrollment posture brief

Registry condition thalassemia

OPEN 5 | RECR 24% | LATE 3 | EARLY 11 | RANK #797 | SPON 2

Nearest open-share peer: Dehydration (24% recruiting · 21 trials)

Anal Cancer42.9%Thalassemia (this)24%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Thalassemia

Thalassemia lists 5 open slots (24% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Thalassemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Thalassemia is recruiting below its size-band peers.

    5 of 21 indexed trials (23.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Thalassemia trials is spread across many organizations.

    UCSF Benioff Children's Hospital Oakland accounts for 2 of 21 trials (9.5%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Most Thalassemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 26 among the 20 trials that report a genuine target (sentinel values excluded). 15 of those (75%) plan for fewer than 100 participants.

  4. Thalassemia research is mostly interventional.

    15 interventional and 6 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 27Phase 33

Open and recent trials

21 total, page 1 of 1

RECRUITING Phase 3 480 participants

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Novo Nordisk A/S

NCT06609226

RECRUITING Early Phase 1 100 participants

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

National Heart, Lung, and Blood Institute (NHLBI)

NCT06313398

RECRUITING Phase 3 26 participants

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated

NCT05477563

RECRUITING Phase 2 24 participants

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

NCT05736419

RECRUITING NA 20 participants

Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia

University of California, San Francisco

NCT07064941

ACTIVE NOT RECRUITING Phase 2 56 participants

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

National Heart, Lung, and Blood Institute (NHLBI)

NCT02105766

ACTIVE NOT RECRUITING Phase 2 20 participants

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Agios Pharmaceuticals

NCT03692052

ACTIVE NOT RECRUITING Phase 3 16 participants

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Vertex Pharmaceuticals Incorporated

NCT05356195

ACTIVE NOT RECRUITING Phase 1 3 participants

A Blood Stem Cell Transplant for Sickle Cell Disease

City of Hope Medical Center

NCT03249831

COMPLETED 423 participants

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

UCSF Benioff Children's Hospital Oakland

NCT01913548

COMPLETED 165 participants

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

Children's Hospital Los Angeles

NCT03715972

COMPLETED 157 participants

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

Westat

NCT05255445

COMPLETED Phase 2 53 participants

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Forma Therapeutics

NCT04987489

COMPLETED 50 participants

Genes Influencing Iron Overload State

St. Jude Children's Research Hospital

NCT01158794

COMPLETED Phase 2 27 participants

Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension

Carelon Research

NCT00872170

COMPLETED 25 participants

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

University of California, San Francisco

NCT03609827

COMPLETED Phase 1 22 participants

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Duke University

NCT00744692

COMPLETED Phase 2 22 participants

Stem Cell Transplant for Hemoglobinopathy

Masonic Cancer Center, University of Minnesota

NCT00176852

COMPLETED 20 participants

Multi-Center Study of Iron Overload: Pilot Study

UCSF Benioff Children's Hospital Oakland

NCT01114776

COMPLETED Phase 2 2 participants

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Dana-Farber Cancer Institute

NCT00153985

COMPLETED Phase 1

Combination Iron Chelation Therapy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00004982

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 7
Phase 3 3

Named interventions

Most-linked intervention names on Thalassemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
3 trials
Pentostatin Drug
2 trials
CTX001 Biological
2 trials
Tacrolimus Drug
2 trials
Alemtuzumab Drug
2 trials
Fludarabine Drug
2 trials
Campath, Fludarabine, Cyclophosphamide Drug
1 trials
Busulfan, Cyclophosphamide, ATG, GCSF Drug
1 trials

US sites by state

Facility locations filed on Thalassemia trials. A trial with sites in several states counts in each.

California 11 trials
New York 6 trials
Tennessee 4 trials
North Carolina 4 trials
Massachusetts 4 trials
Georgia 4 trials
Pennsylvania 2 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Thalassemia page

21 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thalassemia condition card totals 21 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.